The Study
Why isn't an oncogenic mutation in KRAS enough to induce and sustain transformation?
This article doesn't do new experiments—it reads lots of other science papers and puts together what they found. It says KRAS mutations alone don't cause cancer, but they help when other things go wrong too. But it doesn't prove this for sure—it just says it's a good idea based on what others saw in labs.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
KRAS is like a stuck gas pedal — it tells cells to grow, but the cell has safety brakes. If only KRAS is broken, the cell just stops growing (senescence). To get cancer, you also need to break the brakes — like TP53 or p16.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 51 / 100
Quality score
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this explains why some people with KRAS mutations don't get cancer, and why targeting KRAS alone often fails in treatment.
- 2KRAS mutations alone cause senescence in experiments; cancer only forms when TP53, CDKN2A, or PTEN are also lost.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Critical reviews in oncology/hematology
Year
2026
Authors
Juan Iovanna, N. Dusetti
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.